We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical
CPRX

90 hedge funds and large institutions have $134M invested in Catalyst Pharmaceutical in 2015 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more call options, than puts

Call options by funds: $11K | Put options by funds: $8K

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

3% more funds holding

Funds holding: 87 → 90 (+3)

4% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 27

25% less capital invested

Capital invested by funds: $180M → $134M (-$45.6M)

Holders
90
Holders Change
+3
Holders Change %
+3.45%
% of All Funds
2.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
28
Reduced
27
Closed
12
Calls
$11K
Puts
$8K
Net Calls
+$3K
Net Calls Change
-$510K

Top Buyers

1
JP Morgan Chase
JP Morgan Chase
New York
+$3.02M
2
Northern Trust
Northern Trust
Illinois
+$2.68M
3
Invesco
Invesco
Georgia
+$1.78M
4
Allianz Asset Management
Allianz Asset Management
Germany
+$1.75M
5
State Street
State Street
Massachusetts
+$1.59M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.43M
2
CCA
Catalyst Capital Advisors
New York
-$4.34M
3
Franklin Resources
Franklin Resources
California
-$1.66M
4
Morgan Stanley
Morgan Stanley
New York
-$1.39M
5
PVI
Pura Vida Investments
New York
-$1.27M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$22M – – –
CCM
2
Consonance Capital Management
New York
$17.4M +$1.23M +285,000 +5%
Federated Hermes
3
Federated Hermes
Pennsylvania
$13.7M +$79.9K +18,520 +0.4%
BC
4
Broadfin Capital
New York
$12.6M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$7.59M +$577K +133,740 +6%
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$6.62M -$5.43M -1,257,541 -36%
Franklin Resources
7
Franklin Resources
California
$6.38M -$1.66M -384,500 -15%
BFA
8
BlackRock Fund Advisors
California
$5.88M -$80.7K -18,707 -0.9%
SFM
9
Sphera Funds Management
Israel
$3.3M -$432K -100,000 -8%
BIT
10
BlackRock Institutional Trust
California
$3.24M +$1.57M +363,678 +51%
State Street
11
State Street
Massachusetts
$3.1M +$1.59M +369,172 +56%
PA
12
Perceptive Advisors
New York
$2.55M – – –
Allianz Asset Management
13
Allianz Asset Management
Germany
$2.44M +$1.75M +406,327 +100%
Northern Trust
14
Northern Trust
Illinois
$2.29M +$2.68M +621,185 +436%
Deutsche Bank
15
Deutsche Bank
Germany
$2.22M +$1.44M +334,003 +82%
JP Morgan Chase
16
JP Morgan Chase
New York
$2.1M +$3.02M +699,500 New
CCI
17
Columbus Circle Investors
$1.69M +$1.54M +356,066 +171%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.41M +$268K +62,085 +15%
Invesco
19
Invesco
Georgia
$1.24M +$1.78M +411,371 +29,766%
HM
20
HealthCor Management
New York
$1.16M – – –
TI
21
Turner Investments
Pennsylvania
$1.1M +$346K +80,120 +28%
GTC
22
Ghost Tree Capital
New York
$1.05M +$1.51M +350,000 New
BA
23
BlackRock Advisors
Delaware
$1.04M +$532K +123,180 +55%
CCA
24
Catalyst Capital Advisors
New York
$915K -$4.34M -1,005,000 -77%
BIM
25
BlackRock Investment Management
Delaware
$807K -$837 -194 -0.1%
1
2 3 4 5

CPRX Hedge Fund Activity: Q3 2015 in Review

90 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2015, worth a combined $134M — down 25% from $180M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CPRX positions and 12 closed out — a net gain of 3 holders — while 28 added to existing stakes and 27 trimmed.

The largest buyer was JP Morgan Chase, opening a new position worth an estimated $3.02M. The largest seller was Point72 Asset Management, cutting an estimated $5.43M.

  • 90 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2015, up from 87 in Q2 2015.
  • Funds reported $134M of Catalyst Pharmaceutical stock for Q3 2015, down 25% quarter-over-quarter.
  • 15 funds opened new Catalyst Pharmaceutical positions in Q3 2015 and 12 closed out, a net change of +3 holders.
  • The largest Catalyst Pharmaceutical buyer in Q3 2015 was JP Morgan Chase, an estimated $3.02M added.
  • The largest Catalyst Pharmaceutical seller in Q3 2015 was Point72 Asset Management, an estimated $5.43M sold.

Based on aggregated 13F filings for Q3 2015.